CoChat

Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy

Open access
Saitoh, Masakazu, Ishida, Junichi, Ebner, Nicole, Anker, Stefan D., Springer, Jochen, von Haehling, Stephan · 2017 · JCSM Clinical Reports
Cited by 57

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletal muscle, was first described in 1997. It has been known that loss of myostatin function induces an increase in muscle mass in mice, cow, dogs and humans. Therefore, myostatin and its receptor have emerged as a therapeutic target for loss of skeletal muscle such as sarcopenia and cachexia, as well as muscular dystrophies. At the molecular level, myostatin binds to and activates the activin receptor IIB (ActRIIB)/Alk 4/5 complex. Therapeutic approaches therefore are being taken both pre‐clinically and clinically to inhibit the myostatin signaling pathway. Several myostatin inhibitors, including myostatin antibodies, anti‐myostatin peptibody, activin A antibody, soluble (decoy) forms of ActRIIB (ActR II B‐Fc), anti‐myostatin adnectin, ActR II B antibody have been tested in the last decade. The aim of this review is to present the current knowledge of several myostatin inhibitors as a therapeutic approach for patients with loss of skeletal muscle.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.17987/jcsm-cr.v2i1.37

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 57

Metadata

Authors
Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S.
Venue
JCSM Clinical Reports
Publisher
Wiley
Published
2017-01
Volume
2
Issue
1
Pages
1-10
ISSN
2521-3555 (ISSN-L)
OpenAlex
W2766098981
Cited by
57
References
13
FWCI
2.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. https://app.cochat.ai/papers/10.17987/jcsm-cr.v2i1.37
The paper
Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S. (2017). Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. JCSM Clinical Reports. https://doi.org/10.17987/jcsm-cr.v2i1.37

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.